Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials

Dermatology Times·Mar 28

This story is reported by Dermatology Times. Read what other outlets are saying below, then open the original report for full details.